Browsing Tag
FB102
2 posts
VYVGART Sjögren’s setback sends argenx shares lower despite $1.5bn quarterly sales
argenx shares sink after the Phase 3 UNITY failure removes a major VYVGART expansion opportunity despite continued blockbuster sales growth.
Why argenx is buying Forte Biosciences before FB102 enters its bigger proof stage
argenx agrees to buy Forte Biosciences for $2.2 billion. Read how FB102 could reduce Vyvgart concentration risk and reshape ARGX’s autoimmune strategy.